Angiotensin receptor blockers on the formularies of medicare drug plans

Journal of General Internal Medicine

Volumn 22, Issue 8, 2007, Pages 1172-1175

  Gellad, Walid F ^a   Huskamp, Haiden A ^b   Phillips, Kathryn A ^c   Haas, Jennifer S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin receptor blockers; Formularies; Health insurance; Medicare

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; HEALTH SURVEY; HUMAN; MEDICARE; PRESCRIPTION; PUBLICATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COST SHARING; DRUG COSTS; FORMULARIES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE; UNITED STATES;

EID: 34447137396     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0235-z     Document Type: Article

References (20)

1. United States Pharmacopeial Convention Inc. Medicare Prescription Drug Benefit Model Guidelines. Drug Categories and Classes in Part D; 2004 December 31.
2. Bach PB, McClellan MB. The first months of the prescription-drug benefit-a CMS update. N Engl J Med. 2006;354(22):2312-4.
3. Hoadley J, Hargrave E, Cubanski J, Neuman T. An in-depth examination of formularies and other features of Medicare drug plans. The Henry J. Kaiser Family Foundation. April 2006. (Accessed at http://www.kff.org/medicare/upload/ 7489.pdf.)
4. Huskamp HA, Keating NL. The new medicare drug benefit: formularies and their potential effects on access to medications. J Gen Intern Med. 2005;20(7):662-5.
5. Tokmakova M, Solomon SD. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol. 2006;21(4):268-72.
6. Sica DA. ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congest Heart Fail. 2004;10(3):160-4.
7. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952-61.
8. Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther. 1996;60(5):582-8.
9. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637-42.
10. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-7.
11. Retiree Health Benefits Examined: Findings from the Kaiser/Hewitt 2006 Survey on Retiree Health Benefits. December 2006. (Accessed at http://www.kff.org/medicare/upload/7587.pdf.)
12. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood, Va.) 2005;Suppl Web Exclusives:W5-152-W5-66.
13. Consumer Price Index. Federal Reserve Bank of Minneapolis. (Accessed at http://woodrow.mpls.frb.fed.us/research/data/us/calc/hist1913.cfm.)
14. Cohen SB, DiGaetano R, Goskel H. Estimation procedures in the 1996 medical expenditures panel survey household component. Rockville, MD: Agency for Health Care Policy and Research; 1999. Report No.: 99-0027.
15. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13(4 Pt 1):418-26.
16. Frakt AB, Pizer SD. A first look at the new medicare prescription drug plans. Health Aff (Millwood, Va.). 2006;25(4): 252-61.
17. Gold M. Premiums and Cost-Sharing Features in Medicare's New Prescription Drug Program. The Henry J. Kaiser Family Foundation. May 2006. (Accessed at http://www.kff.org/medicare/7517.cfm.)
18. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on medicare drug benefits. N Engl J Med. 2006;354(22):2349-59.
19. Tseng CW, Brook RH, Keeler E, et al. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-60.
20. Mojtabai R. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff (Millwood, Va.). 2003;22(4):220-9.